

CERTIFICATE OF ANALYSIS

Lot#: CHM2210-HE-C

PRODUCT DESCRIPTION

Reference: HuHECS/6+
Product: Cryopreserved Human Hepatocytes
Category: Suspension
Spheroid qualified: NO
(see details below: 3D Spheroid formation section)



Isolation date: 6th May 2022
Initial Isolation Viability: 62.34%
Storage conditions: -196°C using LN₂
Sterility test: negative for bacteria, yeast, and fungi

DONOR DEMOGRAPHICS

Species	Gender	Race	Age	BMI	Smoker	Alcohol Use	Drug Use
Human	Male	Caucasian	59	24.77	No	No	No
Pathology		Serological Data ¹					
Cholangiocarcinoma		Tested negative less than 3 months before surgery					

Patient informed consent was obtained. ¹The donor was serologically tested negative for following infectious diseases: HIV, Hepatitis B and C, and SARS-CoV-2. Donor medical history was also examined prior to accepting this donor. *For donor's medication information, please contact us.*

DONOR HISTOLOGY

Hematoxylin & Eosin staining	Sirius Red staining	Oil red staining
		

- Hematoxylin & Eosin: Most of the parenchyma is populated with healthy hepatocytes, and only in very discrete areas hepatocytes with small lipid vacuolations are visible. From this histological staining, we can observe healthy hepatic tissue.

- Sirius red: Liver with common Sirius red staining, showing usual red stain retention in the portal triads mesenchyme and no bridge fibrosis. Some increased sinusoidal stain retention can be observed, but the present parenchyma is constituted of healthy cells.

- Oil red: Limited number of lipid vesicles stained with Oil Red, showing very discrete and limited areas with fatty hepatocytes. Most of the tissue seems healthy and without fat accumulation.

Conclusions: Liver with rather complete washing (although some erythrocytes or debris are still visible in large and sinusoidal vascular structures), with very limited areas with fatty hepatocytes present and normal matrix deposition throughout whole the parenchyma.


For basic research use only, not to be used for clinical or diagnostic applications. Products distributed by Cytes Biotechnologies may contain human material that should be treated as potentially biohazardous.

CHARACTERIZATION FOR SUSPENSION CELLS

Post Thaw Lot information	Result	SD	n
Number of viable cells/vial:	6.31x10 ⁶	± 0.74x10 ⁶	4
Viability (%):	76.15	± 7.94	4

Human hepatocytes were thawed according to Cytes Biotechnologies protocol. The post-thawing yield and viability (trypan blue exclusion assay) of hepatocytes were assessed after a purification process.

Time (h)	0	0.5	1	1.5	2	3	4	5
Viability (%)	83.14	72.93	60.70	67.82	56.59	63.64	54.59	57.21
SD	± 1.41	± 11.48	± 5.32	± 0.50	± 6.45	± 5.49	± 0.07	± 1.58



Resuspended human hepatocytes suspension (0,5 * 10⁶ cells in 0.5 ml medium) from the post-thaw assessment were incubated up to 5 h at 37°C. The assay was performed in 2 ml round-bottom tubes under shaking conditions (1000 rpm) using Eppendorf Thermomixer C. In the first two hours, samples were taken at every 30 min, after 2 h samples were taken at every 60 min. At each time point the viability of cells was calculated.

3D SPHEROID FORMATION



Spheroid morphology

Cytes **does not guarantee** that these primary hepatocytes will be suitable for 3D culture and creation of spheroid structures.

If you need help for an experiment, just contact us, our experts will be pleased to assist you

CERTIFICATION:

The viability and performance of the primary human hepatocytes provided depend primarily on the use of appropriate media and reagents, as well as the use of sterile plastics. Likewise, proper handling protocols must be followed. Please note that if these parameters are not carefully considered, the cellular response obtained in the assays may be lower than expected.

Name	Title	Signature	Cytes Biotechnologies, S.L.	Date
Pilar Sainz de la Maza	Quality Manager			31/03/23

For basic research use only, not to be used for clinical or diagnostic applications. Products distributed by Cytes Biotechnologies may contain human material that should be treated as potentially biohazardous.

CYTES BIOTECHNOLOGIES, SL.

Parc Científic de Barcelona, C/Baldiri Reixac 4-8 | www.cytesbiotechnologies.com | info@cytesbiotech.com | P.+34 934034553